ReviewClinical epidemiology and global health
Mucormycosis: A deadly black fungus infection among COVID-19 patients in India.
Review in Clinical epidemiology and global health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Pathogens without borders: a review on cross-kingdom transmission strategies and pathogenicity of plant and human pathogens.Archives of microbiology · 2026Review
- Antifungal Policy and Practice Across Five Countries: A Qualitative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- HPathogens (Basel, Switzerland) · 2024Review
- A Systematic Review of the Therapeutic Outcome of Mucormycosis.Open forum infectious diseases · 2024Review
- Trans-kingdom fungal pathogens infecting both plants and humans, and the problem of azole fungicide resistance.Frontiers in microbiology · 2024Review
- Green Chemistry andRecent advances in anti-infective drug discovery · 2024Article
- Coronavirus disease (COVID-19)-associated mucormycosis (CAM): The unholy triad of COVID-19, diabetes mellitus, and corticosteroid therapy.Journal of family medicine and primary care · 2023Article
- The Study of Clinical Profile of Patients With Mucormycosis During COVID-19 Pandemic in Tertiary Care Hospital.Cureus · 2023Article
- Effectiveness of facial palsy protocol among patient with mucormycosis following COVID-19: A case study.Heliyon · 2023Article
- Article
- Infections and immunity: associations with obesity and related metabolic disorders.Journal of pathology and translational medicine · 2023Review
- Machine learning based predictive model and systems-level network of host-microbe interactions in post-COVID-19 mucormycosis.Microbial pathogenesis · 2022Article
- Storm of a rare opportunistic life threatening mucormycosis among post COVID-19 patients: A tale of two pathogens.International journal of critical illness and injury scienceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After first phase of Covid-19, the second wave affects a lot to the Indians with mysterious fungal infection known as Mucormycosis. Here, we reviewed clinical pathogenesis, signs, symptoms and treatment against black fungus. The conclusion revealed that use of immunosuppressant to combat Covid-19 also increases the risk to get infected with mucormycosis. Patients with hyperglycemia, ketoacidosis, solid organ or bone marrow transplantion, liver cirrhosis, neutropenia are more susceptible to get attacked by Mucormycosis moulds. Early diagnosis, removal of predisposing factors, timely antifungal therapy with surgical removal of all infected tissues and adjunctive therapies are four major factors to eradicate Mucormycosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.